- Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501
- Oral presentation at IDWeek 2018 on Saturday, October 6th, 2018, at 11:10 AM PT
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced that, based on the quality and scientific content, the company’s late-breaker abstract, “An Enveloped Virus-like Particle (eVLP) Cytomegalovirus (CMV) Vaccine is Immunogenic and Safe: Results of a First-in-Humans Study,” has been selected for oral presentation at IDWeek 2018, in San Francisco, CA, on October 6, 2018.
Soren Gantt, M.D., Ph.D., M.P.H., Associate Professor with the Division of Infectious Disease in the Department of Pediatrics, University British Columbia Faculty of Medicine, BC Children’s Hospital, and an investigator of the VBI-1501 Phase I study, will deliver the oral presentation. Dr. Gantt’s presentation will discuss the complete safety and immunogenicity dataset from the Phase 1, randomized, placebo-controlled clinical study evaluating the company’s prophylactic CMV vaccine candidate, VBI-1501. This multicenter first-in-humans study was conducted in collaboration with the Canadian Immunization Research Network (CIRN), and showed that VBI-1501 was safe and well tolerated at all doses tested.
Additionally, VBI-1501 was shown to induce gB antibody binding titers at all dose levels, and at the highest dose tested (2.0μg), the vaccine produced a 100% neutralizing antibody seroconversion rate in fibroblast cells, and a 31% seroconversion rate in epithelial cells after the third immunization. Dr. Gantt will provide an overview of this data, and will also highlight the correlate observed between epithelial cell neutralizing antibody activity and higher gB antibody binding titer levels.
According to IDWeek’s website, IDWeek identifies late breaker abstracts as highly competitive, with less than 10 percent of submissions chosen for presentation, and abstracts must contain new, novel, cutting-edge information in order to be considered.
- Session: 213. Late Breaker Oral Abstracts: Influenza and Vaccines
- Date: Saturday, October 6, 2018
- Time: 11:10 AM PDT
- Event Website: https://www.idweek.org